The new instances unify warehouse and data lake queries in a single engine, aiming to reduce complexity and eliminate unpredictable Spectrum charges. AWS has released new Graviton-powered RG instances ...

Biopharma companies appear to be more willing to go public after a long drought. Just this week, GLP-1 developer Kailera Therapeutics and proteomics company Alamar Biosciences launched IPO roadshows ...

AWS has now unveiled Amazon Bio Discovery, an AI platform that grants researchers direct access to a broad library of biological foundation models that can be fine-tuned for specific use cases in drug ...

Amazon.com on Monday announced it reached a new agreement with the U.S. Postal Service on package deliveries, and sources said the cash-strapped mail system would retain about 80% of its existing ...

Using the James Webb Space Telescope (JWST), astronomers have discovered a new red galaxy at a redshift of approximately 11.45. The newfound galaxy, which received designation EGS-z11-R0, turns out to ...

Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Forbes contributors publish independent expert analyses and insights. Pam Danziger reports on retail, focused on the luxury consumer market. Amazon is calling it quits on its Fresh grocery and Amazon ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

A run of pharmaceutical mergers and acquisitions is fueling optimism that biotechnology venture capital is poised to rebound from its postpandemic slump. With $223 billion in biotech M&A deals ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.